Drug Profile
Nadecnemab - Regeneron Pharmaceuticals
Alternative Names: REGN-5069Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals
- Class Analgesics; Antibodies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pain
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for phase-I development in Pain(In volunteers) in Belgium (IV, Infusion)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Pain(In volunteers) in Belgium (SC, Injection)
- 29 Oct 2020 Regeneron Pharmaceuticals terminates phase II trial in Pain in USA, Georgia, Moldova, Ukraine, Poland, Spain, Belgium, United Kingdom (IV) (EudraCT2018-004730-15) (NCT03956550)